The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Lokavant provides clinical trial intelligence
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Subscribe To Our Newsletter & Stay Updated
